Medicenna Therapeutics Corp

Company Profile

Medicenna Therapeutics Corp had its IPO on 2001-08-27 under the ticker symbol MDNA.

The company operates in the Healthcare sector and Biotechnology industry. Medicenna Therapeutics Corp has a staff strength of 16 employees.

Stock update

Shares of Medicenna Therapeutics Corp opened at $0.31 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.3 - $0.31, and closed at $0.3.

This is a -2.68% slip from the previous day's closing price.

A total volume of 128,080 shares were traded at the close of the day’s session.

In the last one week, shares of Medicenna Therapeutics Corp have slipped by -18.46%.

Medicenna Therapeutics Corp's Key Ratios

Medicenna Therapeutics Corp has a market cap of $26.29 million, indicating a price to book ratio of 1.3961 and a price to sales ratio of 0.

In the last 12-months Medicenna Therapeutics Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-16436500. The EBITDA ratio measures Medicenna Therapeutics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Medicenna Therapeutics Corp’s operating margin was 0% while its return on assets stood at -39.74% with a return of equity of -39%.

In Q2, Medicenna Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Medicenna Therapeutics Corp’s PE and PEG Ratio

Forward PE

208.3333

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.1 per share while it has a forward price to earnings multiple of 208.3333 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Medicenna Therapeutics Corp’s profitability.

Medicenna Therapeutics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.0116. Its price to sales ratio in the trailing 12-months stood at 0.

Medicenna Therapeutics Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$31.55 million

Total Liabilities

$3.23 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Medicenna Therapeutics Corp ended 2024 with $31.55 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.55 million while shareholder equity stood at $26.90 million.

Medicenna Therapeutics Corp ended 2024 with $0 in deferred long-term liabilities, $3.23 million in other current liabilities, 100924000.00 in common stock, $-83843000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.62 million and cash and short-term investments were $29.62 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Medicenna Therapeutics Corp’s total current assets stands at $31.49 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $835000.00 compared to accounts payable of $0 and inventory worth $0.

In 2024, Medicenna Therapeutics Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Medicenna Therapeutics Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.3

52-Week High

$0.966

52-Week Low

$0.298

Analyst Target Price

$6.66

Medicenna Therapeutics Corp stock is currently trading at $0.3 per share. It touched a 52-week high of $0.966 and a 52-week low of $0.966. Analysts tracking the stock have a 12-month average target price of $6.66.

Its 50-day moving average was $0.41 and 200-day moving average was $0.55 The short ratio stood at 0.66 indicating a short percent outstanding of 0%.

Around 2365.1% of the company’s stock are held by insiders while 1356.7% are held by institutions.